{"disease":{"id":"relapsed-acute-myelogenous-leukemia","name":"relapsed acute myelogenous leukemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03081780","title":"Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT00939653","title":"T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Therapeutic Advances in Childhood Leukemia Consortium","has_results":true},{"nct_id":"NCT01743807","title":"Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Therapeutic Advances in Childhood Leukemia Consortium","has_results":true},{"nct_id":"NCT05321940","title":"Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Juan C. Ramos, MD","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}